🔎 Trials Near Me

Home › Post-COVID Conditions (Long COVID) › NCT05833217

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

RecruitingHealthy volunteers welcome

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 Infection and Inflammation in Human Adipose Tissue

Who can join

Ages 18 to 80 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Ages 18 to 80
* BMI ≥ 25 kg/m2
* not currently pregnant

Exclusion Criteria:

Arm 2 (Adipose Tissue Biopsy) exclusions include

* pregnancy
* prior liposuction
* recent change in weight (\> 2 kg in one month)
* bleeding disorders
* anticoagulant use

Arm 3 (healthy controls only) exclusions include patients with

* major organ disease
* diabetes
* history of liposuction
* bariatric surgery
* eating disorders
* psychiatric disorders
* pregnancy or lactation
* recent change in weight (over the past 12 weeks),
* use of weight loss medication or oral steroids
* hematocrit \< 33%
* fasting glucose \>= 126 mg/dL
* blood pressure \>160/100 mmHg

About the study

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

What is being tested

Sponsor: Stanford University · Participants: 55 · Started: Jun 6, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05833217

Locations in the U.S.

CaliforniaStanford Health, Palo Alto

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.